Abstract
Objective
Transient Epileptic Amnesia (TEA) is a form of adult-onset epilepsy where presenting features are well described, but little is known regarding prognosis. This study aimed to elucidate the long-term prognosis of TEA regarding seizure control, memory, medical comorbidities and life expectancy.
Methods
Up-to-date clinical information was collected for 47 people diagnosed with TEA who had joined the TIME study 10 years earlier. At entry to the study, information about comorbid conditions was systematically collected. Details regarding subsequent diagnoses, seizure activity, changes to treatment, or reports of cognitive impairment were obtained through the family doctor. The variables of interest were compared with UK population data.
Results
Mortality in the cohort was 21/47 (45%), with an average age at death of 82.5 years. Seizures remained well-controlled for the majority but required adjustments in dose and type for some (28%). A small number (3 cases) remained seizure-free without medication. History of cardiovascular disorders was frequent (78.7%), typically involving hypertension (55.3%). Autoimmune disorders (25.5%), cancer (23.4%) and depression (21.3%) were also commonly reported. While persisting memory problems were often noted, dementia was diagnosed in 7 cases (14.9%). Life expectancy and comorbidities in TEA did not differ from available population norms.
Significance
Results suggest that life expectancy is not reduced in TEA. While TEA does not appear to be a self-limiting form of epilepsy, seizures are typically well-controlled via medication. As adjustments to medication may be required, even after long periods of stability, ongoing medical monitoring is recommended. Co-morbid vascular disorders are frequent but appear similar to general population estimates. Monitoring mood may be important, given people with chronic conditions are often vulnerable to depression. Given persisting memory difficulties, development of effective memory interventions for people with TEA is warranted.
MAR